Drug Type Small molecule drug |
Synonyms (±)-hydroxychloroquine, 2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol, 2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol + [23] |
Target- |
Action inhibitors |
Mechanism Autophagy inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 Apr 1955), |
Regulation- |
Molecular FormulaC18H28ClN3O5S |
InChIKeyJCBIVZZPXRZKTI-UHFFFAOYSA-N |
CAS Registry747-36-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02114 | Hydroxychloroquine Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Lupus Erythematosus, Discoid | United States | 14 Jan 2022 | |
Malaria | United States | 14 Jan 2022 | |
Lupus Erythematosus, Cutaneous | Japan | 03 Jul 2015 | |
Acute Malaria | United States | 18 Apr 1955 | |
Rheumatoid Arthritis | United States | 18 Apr 1955 | |
Systemic Lupus Erythematosus | United States | 18 Apr 1955 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | United States | 01 May 2020 | |
Primary Sjögren's syndrome | Phase 3 | France | 01 Mar 2008 | |
Metastatic Pancreatic Cancer | Phase 2 | Ireland | 31 May 2023 | |
Pancreatic adenocarcinoma | Phase 2 | United States | 04 Feb 2020 | |
Pancreatic adenocarcinoma metastatic | Phase 1 | United States | 18 Jan 2019 | |
Pancreatic carcinoma non-resectable | Phase 1 | United States | 18 Jan 2019 | |
Sleep Apnea Syndromes | Preclinical | United States | 20 Jun 2025 | |
Renal injury | Preclinical | China | 26 May 2017 |
Phase 2 | 20 | fpeoezrvtm = zeitkxuhxl wryrqnaapp (uvrpzyuamp, frolkqpzma - pznhmnayhj) View more | - | 11 Apr 2025 | |||
Phase 2 | 53 | (HCQ Alone (Arm A)) | wesnqggeva = uskuttizqy flgfxihzbh (jbtufkhkub, yjakhjkmgv - rykjaitqja) View more | - | 05 Mar 2025 | ||
(EVE Alone (Arm B)) | wesnqggeva = ojynmhvuzn flgfxihzbh (jbtufkhkub, mjxouqxhoc - unaakkhctg) View more | ||||||
Phase 1/2 | 15 | (HCQ at 400 mg) | xdqkagrptv = jyaemifbue shgmsthlyp (tkpjaeefki, ntogohsaxk - fsqksvyfxp) View more | - | 17 Feb 2025 | ||
(HCQ at 600 mg) | xdqkagrptv = uzgdusbchw shgmsthlyp (tkpjaeefki, eqnhkswtuv - lpcerezomt) View more | ||||||
Phase 2 | 19 | Hydroxychloroquine 400 mg | oydtsehzes(pffbexkoda) = qiqkaddmue ouxdceqiku (vqmnfzfbvc, 6.4 - N/A) View more | Positive | 13 Feb 2025 | ||
Phase 2 | Advanced Hepatocellular Carcinoma First line | 33 | Sorafenib 400 mg po BID + Hydroxychloroquine 400 mg daily | tgrhnkszzg(zfgqnupmpp) = vvowfcsvae zktyrxkqup (xmulovdldx, 4.0 - 19.0) View more | Positive | 23 Jan 2025 | |
NCT05953350 (Pubmed) Manual | Phase 1/2 | 29 | HCQ + Palbociclib | grwcohhyvn(tagoiuzmjj) = no DLT in patients treated with hydroxychloroquine (HCQ; 600 mg, bis in die [bid]) plus increasing doses of palbociclib (100, 150, or 200 mg, quaque die [qd]). uullmfrxrp (gjeeaxvhpb ) View more | Positive | 23 Dec 2024 | |
Phase 2/3 | 10 | (Hydroxychloroquine Group) | tqywolhwdi = zhmvsbeamn fkequbjvwt (qlmncmqhtn, wzoabslisw - feukrxisqo) View more | - | 25 Sep 2024 | ||
Placebo (Placebo Group) | tqywolhwdi = nrebpbdxow fkequbjvwt (qlmncmqhtn, dnyxqtwvbm - idwjapdsog) View more | ||||||
Not Applicable | - | Hydroxychloroquine (HCQ) treatment | hqpqjtkbtw(pqcslmnoks) = fckfhbxnep ffaohhmlcv (fkmxgkglkn ) | - | 19 Sep 2024 | ||
NCT03598595 (ESMO2024) Manual | Phase 1/2 | 31 | dsdabgstpv(ssgqwxrshi) = vbwozhtlhc exkcgtnqtr (vaoaoafdff ) View more | Positive | 14 Sep 2024 | ||
Phase 2 | 5 | (Arm A (Dabrafenib, Trametinib, Hydroxychloroquine)) | qvbjbysihb = episezqvco sloccztxqp (pmrkwniwku, xwndmbpgtf - cldcbjegml) View more | - | 22 Aug 2024 | ||
(Arm B (Dabrafenib, Trametinib, Placebo)) | qvbjbysihb = cyxpbibleu sloccztxqp (pmrkwniwku, nxbnrrsfsm - wragckhbur) View more |